EXT2 promotes sarcoma progression and immune evasion via the AKT/c-Myc/PD-L1 axis: a multi-omics and validation study.
APA
Qin H, Qi T, et al. (2026). EXT2 promotes sarcoma progression and immune evasion via the AKT/c-Myc/PD-L1 axis: a multi-omics and validation study.. Journal of translational medicine, 24(1). https://doi.org/10.1186/s12967-026-07956-y
MLA
Qin H, et al.. "EXT2 promotes sarcoma progression and immune evasion via the AKT/c-Myc/PD-L1 axis: a multi-omics and validation study.." Journal of translational medicine, vol. 24, no. 1, 2026.
PMID
41857664
같은 제1저자의 인용 많은 논문 (5)
- Endothelial circadian rhythm genes as prognostic modulators of tumor progression and immune interactions: insights from pan-cancer single-cell RNA sequencing.
- Integrated multi-omics analysis reveals that MARCKS reprograms the immunosuppressive microenvironment to drive hepatocellular carcinoma progression.
- Autologous Auricular Cartilage-Augmented Porous High-Density Polyethylene Grafts for Nasal Tip Plasty in Female Revision Rhinoplasty.
- Cuproptosis-associated PDHA1 promotes sarcoma progression and immunotherapy responsiveness via the E2F1-PD-L1 axis: a multi-omics and clinical validation study.
- Efficacy and Safety Analysis of Transarterial Chemoembolization Combined with Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma.